Jim Simons Amryt Pharma PLC Transaction History

Renaissance Technologies LLC

8 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2023 May 12, 2023	BUY	$7.0 - $14.77 $354,900 - $748,839	50,700 Added 105.62%	98,700 $1.44 Million
Q4 2022 Feb 13, 2023	BUY	$6.68 - $7.58 $2,004 - $2,274	300 Added 0.63%	48,000 $350,000
Q3 2022 Nov 14, 2022	BUY	$6.8 - $8.01 $5,440 - $6,408	800 Added 1.71%	47,700 $330,000
Q2 2022 Aug 12, 2022	BUY	$6.85 - $8.87 $144,535 - $187,156	21,100 Added 81.78%	46,900 $328,000
Q1 2022 May 13, 2022	BUY	$6.3 - $10.86 $49,770 - $85,794	7,900 Added 44.13%	25,800 $213,000
Q4 2021 Feb 11, 2022	BUY	$9.44 - $12.24 $168,976 - $219,096	17,900 New	17,900 $193,000
Q3 2021 Nov 12, 2021	SELL	$9.63 - $12.47 $214,749 - $278,081	-22,300 Closed	0 $0
Q2 2021 Aug 13, 2021	BUY	$10.9 - $14.29 $243,070 - $318,667	22,300 New	22,300 $270,000

142K

Ticker AMYT
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—Specialty & Generic
Shares Outstandng 64,177,000
Description
Amryt Pharma plc, a commercial-stage biopharmaceutical company, focuses on acquiring, developing, and commercializing various treatments to help improve the lives of patients with rare and orphan diseases. The company provides metreleptin, an adjunct to diet as replacement therapy to treat the complications of leptin deficiency in patients with ...

Get notified when there are updates to the investment portfolio of Renaissance Technologies LLC, based on Form 13F filings with the SEC.

Stay updated on Renaissance Technologies LLC and Jim Simons with notifications on news.